Stable Angina: Symptoms, Treatment, Safety and Funding of the Evidence
Stable angina versus changing chest pain, assessment, symptom relief, prevention goals and supplement limitations.
Evidence-graded research on heart and cardiovascular health — what trials and regulators show about omega-3, CoQ10 and other supplements, conflicts disclosed.
Stable angina versus changing chest pain, assessment, symptom relief, prevention goals and supplement limitations.
Coronary artery disease, obstructive and nonobstructive patterns, assessment, treatment choices, supplement limits and funding explained.
AF care separates stroke prevention from rhythm control. Evidence, supplement limits, interactions and source funding explained.
Heart-failure types, current treatment guidance, rehabilitation, CoQ10 limits, potassium safety and who funded the evidence.
Propranolol for anxiety and stage fright: what independent reviews show, why the evidence is weak, the HSIB overdose warning, asthma risks and who funds it.
Current DMARD guidance and the limits of omega-3, curcumin, diet and other adjunct studies, with original-source access and financial disclosures.
Small nattokinase BP trials have commercial ties and a pooling concern. Laboratory clot degradation and human blood-marker findings do not establish Long COVID recovery or patient microclot clearance; bleeding, medicines and product composition need careful review.
Psyllium has bulk-forming laxative use and positive pooled lipid and diabetes-marker findings, with substantial variation and trial limitations. Soluble fiber is guideline-recommended for global IBS symptoms; cited reviews do not establish GLP-1-equivalent weight loss. Adequate fluid, swallowing and bowel risks, allergy and medicine-specific timing matter. Commercial disclosures and unresolved financial terms prevent a blanket independence claim.
Garlic trials report modest blood-pressure reductions. Review preparation differences, study funding, evidence limits and bleeding-related precautions.
Berberine studies suggest short-term glucose and lipid-marker changes, but do not establish a prescription-drug substitute. Formulation, funding, trial quality and medication interactions matter.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.